The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | The current treatment landscape of PNH in Germany and across Europe
In this video, Jens Panse, MD, Aachen University Hospital, Aachen, Germany, comments on the current treatment landscape of paroxysmal nocturnal hemoglobinuria (PNH) in Europe. In Germany, there are six approved agents, including three terminal inhibitors (eculizumab, ravulizumab, and crovalimab) and three proximal inhibitors (iptacopan, danicopan, and pegcetacoplan), with varying availability across European countries due to differing reimbursement policies. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are differences in approval and availability. Basically, if I start from Germany, there are six agents approved. There are three terminal inhibitors and there are three proximal inhibitors. There’s eculizumab, there’s ravulizumab, and there’s crovalimab. Of course, there’s the eculizumab biosimilars, so those would be other agents. and then you have the proximals with iptacopan, danicopan and pegcetacoplan...
There are differences in approval and availability. Basically, if I start from Germany, there are six agents approved. There are three terminal inhibitors and there are three proximal inhibitors. There’s eculizumab, there’s ravulizumab, and there’s crovalimab. Of course, there’s the eculizumab biosimilars, so those would be other agents. and then you have the proximals with iptacopan, danicopan and pegcetacoplan. However, while in Germany all these drugs are reimbursed and you can choose between all of them, in other European countries reimbursement is not made for all of those drugs. So the availability also depends on what your healthcare system provides for you. So these drugs are licensed but not available for every patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting fees: Alexion, Sobi, Omeros, Sandoz; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Alexion, Amgen, Apellis, AstraZeneca, Blueprint Medicines, BMS, Boehringer Ingelheim, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Sobi; Support for attending meetings and/or travel: Alexion, Blueprint Medicines, Boehringer Ingelheim, Novartis, Omeros, Pfizer, Roche, Sobi; Participation on a Data Safety Monitoring Board or Advisory Board: Alexion, Amgen, Apellis, AstraZeneca, Blueprint Medicines, BMS, Boehringer Ingelheim, Gilead, MSD, Novartis, Omeros, Pfizer, Roche, Sanofi, Sobi; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: www.lichterzellen.de; Receipt of equipment, materials, drugs, medical writing, gifts or other services: Apellis, Blueprint Medicines, Novartis, Roche, Sobi.
